LifeMD, Inc. (LFMD) Stock Price & Analysis
LifeMD, Inc. (LFMD) closed at USD 2.46 on Thursday, October 15, 2026, up 3.80% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.37; the Oct 15, 2026 session ranged USD 2.34–2.5 on volume of 737,015 shares. Market capitalization is $118.71M, with a 52-week range of USD 2.34–6.44 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LFMD.md
Key facts (LFMD)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 8.13 (range 5–15).
- Total return with dividends: 1Y -61.7% vs S&P 500 +18.1%; 5Y -52.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD -0.01, revenue estimate $48.9M.
Analysts (LFMD)
Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 8.13 (low 5, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-17 | HC Wainwright & Co. | Reiterated | Buy | $9 |
| 2026-08-07 | HC Wainwright & Co. | Target lowered | Buy | $10 → $9 |
| 2026-08-06 | B. Riley Securities | Target lowered | Buy | $10 → $8 |
| 2026-08-06 | BTIG | Target lowered | Buy | $10 → $9 |
Total return (dividends reinvested) (LFMD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -61.7% | -52.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -61.9% | -13.8% |
| Volatility (annualized) | 78.3% | 79.9% |
| Max drawdown | -63.1% (Oct 2025→Oct 2026) | -83.3% (Jun 2025→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 2.46 |
|---|---|
| Change | ▲ 3.80% (up) |
| Previous Close | USD 2.37 |
| Open | USD 2.36 |
| Day Range | USD 2.34 – 2.5 |
| 52-Week Range | USD 2.34 – 6.44 |
| Volume | 737,015 shares |
| Market Cap | $118.71M |
| Exchange | NGM |
Technical Analysis (LFMD)
Nexqual's technical model rates LFMD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.42 (neutral) |
| vs SMA50 | Below (USD 3.08) |
| MACD | -0.2 (negative) |
Analyst Ratings (LFMD)
Wall Street analysts rate LFMD "Buy" based on 8 analysts, with a mean price target of USD 8.13 (range USD 5–15), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 8.13 |
| High Target | USD 15 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (LFMD)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $48.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.15 vs est -0.05 ▼ miss |
| 2026-03-31 | USD -0.15 vs est -0.13 ▼ miss |
| 2025-12-31 | USD 0.06 vs est 0.09 ▼ miss |
| 2025-09-30 | USD -0.08 vs est 0.05 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (LFMD)
| Total Revenue | $191.59M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -3.50% |
| Gross Margin | +87.50% |
| Operating Margin | -15.08% |
| Profit Margin | +0.10% |
| ROE | -515.90% |
| Debt / Equity | 0.76 |
| Current Ratio | 0.9 |
| Total Cash | $25.14M |
| Total Debt | $6.02M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (LFMD)
Nexqual rates LifeMD, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Weak — Revenue -9% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 88%, operating -15% |
| Balance Sheet | Weak — $25M cash vs $6M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -516%, ROA -18.9% |
Ownership (LFMD)
| Insider Ownership | +15.80% |
|---|---|
| Institutional Ownership | +47.35% |
| Shares Outstanding | 48.26M |
| Float | 39.66M |
| Short % of Float | +18.74% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (LFMD)
LifeMD, Inc. is led by Justin Schreiber (age 42), Chairman & CEO, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Chairman & CEO | Justin Schreiber (age 42) |
|---|---|
| Chief Operating Officer | Shayna Webb Dray (age 38) |
| Chief Financial Officer | Atul Kavthekar |
| Chief Technology Officer | Umesh Sripad |
| Chief Marketing Officer | Chris Pisano (age 50) |
Major Backers & Investors (LFMD)
Notable institutional backers of LifeMD, Inc. include Federated Hermes, Inc., Renaissance Technologies, Prescott Group Capital Management, L.L.C., according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 10.64% |
| Renaissance Technologies | 2.24% |
| Prescott Group Capital Management, L.L.C. | 1.86% |
| Bridge Builder Trust-Bridge Builder Small/Mid Cap Growth Fund | 1.43% |
| Brc Group Holdings, Inc. | 1.32% |
| Royce & Associates LP | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.02% |
| Vanguard Group | 7.13% |
| State Street | 3.83% |
| Geode Capital | 2.22% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CARL | Carlsmed, Inc. | USD 13.95 | ▼ 3.59% |
| CTEV | Claritev Corporation | USD 23.86 | ▲ 0.59% |
| NRC | NRC Health | USD 21.11 | ▲ 4.66% |
| EVH | Evolent Health, Inc | USD 4.87 | ▲ 5.87% |
| WEAV | Weave Communications, Inc. | USD 7.39 | ▲ 0.27% |
| SOPH | SOPHiA GENETICS SA | USD 7.29 | ▲ 2.82% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt